Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer
    Journal Article

    Hoimes, C. J.; Flaig, T. W.; Milowsky, M. I.; Friedlander, T. W.; Bilen, M. A.; Gupta, S.; Srinivas, S.; Merchan, J. R.; McKay, R. R.; Petrylak, D. P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
    Meeting Abstract

    Deming, D. A.; Rodon Ahnert, J.; Demeure, M. J.; Federman, N.; McKean, M.; Lee, E. K.; Spira, A. I.; Kwiatkowski, D. J.; Hussein, M. A.; Gordon, E. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Durvalumab plus olaparib in previously untreated, platinum-ineligible patients with metastatic urothelial carcinoma: A multicenter, randomized, phase II trial (BAYOU)
    Journal Article

    Rosenberg, J. E.; Park, S. H.; Kozlov, V.; Dao, T. V.; Castellano, D.; Li, J. R.; Mukherjee, S. D.; Howells, K.; Dry, H.; Lanasa, M. C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study
    Meeting Abstract

    Park, W.; O'Reilly, E. M.; Furuse, J.; Li, C. P.; Oh, D. Y.; Garcia-Carbonero, R.; Roth, G.; Lee, H. J.; Bhattacharya, P. P.; Moran, D. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • The SHARON trial: A study of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cell rescue for metastatic pancreatic cancer with an inherited BRCA mutation
    Meeting Abstract

    Yu, K. H.; Weekes, C. D.; Chen, Y. B. A.; Glazier, J. A.; Glazier, A.; Dahi, P.; Giralt, S.; O'Reilly, E. M.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • APOLLO: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2 or PALB2 mutation—ECOG-ACRIN EA2192
    Meeting Abstract

    Reiss, K. A.; Hong, S. C.; Kasi, A.; O'Reilly, E. M.; Maithel, S. K.; Yao, X.; Hamilton, S. R.; Boursi, B.; Pishvaian, M. J.; Klempner, S. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) and biomarkers in daNIS-2, a phase III study comparing NIS793 plus nab-paclitaxel/gemcitabine (NG) vs placebo plus NG in first-line (1L) metastatic pancreatic ductal adenocarcinoma (mPDAC)
    Meeting Abstract

    Wainberg, Z. A.; Macarulla, T.; Golan, T.; Ikeda, M.; Milella, M.; Taieb, J.; Wang, L.; Gyambibi, N.; López, E. M.; Bento Pereira da Silva, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations
    Meeting Abstract

    Tolcher, A. W.; Park, W.; Wang, J. S.; Spira, A. I.; Janne, P. A.; Lee, H. J.; Gill, S.; LoRusso, P.; Herzberg, B.; Goldman, J. W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) and biomarker assessments in daNIS-3, a phase II platform study of NIS793 (anti–TGF-β monoclonal antibody) and other investigational drug combinations with standard of care (SOC) vs SOC alone in patients (pts) with second-line metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Kopetz, S.; Kasper, S.; Rivera, F.; Tournigand, C.; Cheng, Y.; Deshpande, P.; D'Alessio, D.; Amirouchene Angelozzi, N.; Bento Pereira da Silva, A.; Segal, N. H.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Genetic profiling analysis design of well-differentiated aggressive grade 2 and 3 gastroenteropancreatic neuroendocrine tumors in the phase III randomized controlled COMPOSE trial
    Meeting Abstract

    Halfdanarson, T. R.; Capdevila, J.; Halperin, D. M.; Herrmann, K.; Kong, G.; Leyden, S.; Mailman, J.; Reidy-Lagunes, D.; Srirajaskanthan, R.; Erdö, M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save